Arrowstreet Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Arrowstreet Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-66,244	Closed	-$517K	–	1843
2025 Q4	$517K	Sell	66,244 -5,159,742	-99%	-$37.3M	﹤0.01%	1672
2025 Q3	$39.7M	Buy	5,225,986 +947,431	+22%	+$7.89M	0.03%	529
2025 Q2	$38.3M	Buy	4,278,555 +4,084,403	+2,104%	+$38M	0.03%	494
2025 Q1	$1.46M	Sell	194,152 -209,260	-52%	-$1.69M	﹤0.01%	1388
2024 Q4	$3.03M	Sell	403,412 -27,818	-6%	-$211K	﹤0.01%	1162
2024 Q3	$3.28M	Buy	+431,230	New	+$3.28M	﹤0.01%	1096
2014 Q3	–	Sell	-36,011	Closed	-$459K	–	985
2014 Q2	$459K	Buy	+36,011	New	+$350K	﹤0.01%	840

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Arrowstreet Capital's BCRX Position: Q1 2026 in Review

Arrowstreet Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 66,244 shares — an estimated $517K sold.

Arrowstreet Capital first reported a position in BCRX in Q2 2014 and held it in 7 quarters. The position peaked at $39.7M in Q3 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Arrowstreet Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Arrowstreet Capital sold 66,244 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $517K.
Arrowstreet Capital first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 7 quarters.
Arrowstreet Capital's BioCryst Pharmaceuticals position peaked at $39.7M in Q3 2025.
302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.